Vitrolife to acquire Igenomix for EUR 1.25B

Swedish medical technology group Vitrolife agreed to buy reproductive genetic testing services provider Igenomix for EUR 1.25 billion from private equity group EQT and other shareholders.

“Swedish medical technology group Vitrolife said on Thursday it would buy reproductive genetic testing services provider Igenomix S.L. in a deal worth 1.25 billion euros ($1.48 billion).”reuters.com

• 1 source
• reuters.comSweden's Vitrolife to buy Igenomix in EUR 1.25 billion dealJul 8, 2021

Summarized from public sources; check the original articles before acting on it.